Lenalidomide and venous thrombosis in multiple myeloma [22]

New England Journal of Medicine

Volumn 354, Issue 19, 2006, Pages 2079-2080

  Knight, Robert ^a   DeLap, Robert J ^a   Zeldis, Jerome B ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DEXAMETHASONE; ERYTHROPOIETIN; LENALIDOMIDE; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE; THALIDOMIDE;

HUMAN; LETTER; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; VEIN THROMBOSIS; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; RANDOMIZED CONTROLLED TRIAL;

ANTI-INFLAMMATORY AGENTS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; HUMANS; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS; THALIDOMIDE; VENOUS THROMBOSIS; ERYTHROPOIETIN; MULTIVARIATE ANALYSIS;

EID: 33646494190     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc053530     Document Type: Letter

References (3)

1. Bartlett JB, Tozer A, Stirling D, Zeldis JB. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 2005;93:613-9.
2. Dimopoulos M, Weber D, Chen C, et al. Evaluating oral lenalidomide (Revlimid) and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica 2005;90:Suppl 2:160. abstract.
3. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005;80:1568-74.